Richard M. Stone, MD

    Richard M. Stone, MD

    Clinical director of the Adult Acute Leukemia Program at the Dana-Farber Cancer Institute in Boston
    • Teaching Old Drugs New Tricks? Thursday, March 1st, 2018

      When the U.S. Food and Drug Administration (FDA) approved CPX-351 (a fixed combination of daunorubicin and cytarabine), it appeared that everything old was new again. The drug, which is a combination of two existing generic drugs encased in a liposome, received breakthrough-therapy designation in August 2017 for the treatment of adults with newly diagnosed, therapy-related [...]

    • FLT3 Inhibitors in Older Patients with Acute Myeloid Leukemia: More Questions Than Answers? Friday, July 1st, 2016

      Acute myeloid leukemia (AML) affects primarily older adults (with a median age of 67 years at diagnosis), and management of the disease in this population represents a therapeutic challenge – given their comorbidities and susceptibility to treatment-related toxicities. Patients who also harbor the FLT3 mutation face a particularly poor prognosis, with a high chance of [...]